Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
CEO | Dr. Amit Kumar Ph.D. |
IPO Date | Jan. 1, 1987 |
Location | United States |
Headquarters | 3150 Almaden Expressway, San Jose, CA, United States, 95118 |
Employees | 4 |
Sector | Healthcare |
Industry | Biotechnology |
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
NA
NA
NA
NA
NA
NA
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email